Cargando…
Current and future alternative therapies for beta-thalassemia major
Beta-thalassemia is a group of frequent genetic disorders resulting in the synthesis of little or no β-globin chains. Novel approaches are being developed to correct the resulting α/β-globin chain imbalance, in an effort to move beyond the palliative management of this disease and the complications...
Autores principales: | de Dreuzy, Edouard, Bhukhai, Kanit, Leboulch, Philippe, Payen, Emmanuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chang Gung University
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138429/ https://www.ncbi.nlm.nih.gov/pubmed/27105596 http://dx.doi.org/10.1016/j.bj.2015.10.001 |
Ejemplares similares
-
The Future of Gene Therapy for Transfusion-Dependent Beta-Thalassemia: The Power of the Lentiviral Vector for Genetically Modified Hematopoietic Stem Cells
por: Rattananon, Parin, et al.
Publicado: (2021) -
High-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing
por: Ling, Chen, et al.
Publicado: (2016) -
Ex Vivo Selection of Transduced Hematopoietic Stem Cells for Gene Therapy of β-Hemoglobinopathies
por: Bhukhai, Kanit, et al.
Publicado: (2018) -
Coagulopathy in Beta-Thalassemia: Current Understanding and Future Perspectives
por: Cappellini, M. Domenica, et al.
Publicado: (2009) -
Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease
por: Negre, Olivier, et al.
Publicado: (2015)